[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368128-105":59,"doc-detail-368128-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","praf2-as-a-novel-biomarker-for-breast-cancer-with-machine-learning-and-experimentation-validation","PRAF2 as a novel biomarker for breast cancer with machine learning and experimentation validation","","Breast cancer remains the most prevalent malignancy among women, and identifying actionable therapeutic targets is critical. This study investigates PRAF2, previously implicated as an oncogene in breast cancer, to clarify its role in cancer promotion. Pan-cancer bioinformatics analyses assess prognostic and immune-infiltration associations, followed by experimental validation of PRAF2 expression in institutional samples. PRAF2 knockdown in two breast cancer cell lines reduces cell proliferation, including CCK-8 and wound-healing assays.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/praf2-as-a-novel-biomarker-for-breast-cancer-with-machine-learning-and-experimentation-validation/368128/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/praf2-as-a-novel-biomarker-for-breast-cancer-with-machine-learning-and-experimentation-validation/368128.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in breast cancer research?","Question",{"text":112,"@type":113},"The study targets the need for novel therapeutic biomarkers, focusing on PRAF2 whose mechanism in breast cancer promotion is not fully understood.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the prognostic value of PRAF2 evaluated?",{"text":117,"@type":113},"Prognostic associations were analyzed using multiple databases, with specific investigation of prognostic value in GEPIA.",{"name":119,"@type":110,"acceptedAnswer":120},"What experimental validation was performed after bioinformatics analysis?",{"text":121,"@type":113},"PRAF2 expression was validated in institutional breast cancer samples, and PRAF2 was downregulated in two breast cancer cell lines to test effects on viability, proliferation, and migration using assays such as CCK-8 and wound healing.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368128,1790794658,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Wang et al. BMC Cancer (2025) 25:32 [https://doi.org/10.1186/s12885-024-13258-7](https://doi.org/10.1186/s12885-024-13258-7)  \nBMC Cancer  \n RESEARCH Open Access  \nPRAF2 as a novel biomarker for breast cancer with machine learning and experimentation validation  \nZheng Wang1†, Zilin Bi1†, Hongguang Bo1†, Junyi Xu2†, Rui Sha1, Zhaocai Yin1, Changsheng Yu1, Yufa Xu1, Xiaomeng Shi1, Wenbo Song3, Bin Chen1, Yabing Wang1*, Qian Zhang4* and Jianping Chen1*  \nAbstract  \nBackground Breast cancer (BC) is the most prevalent malignancy in women. Potential therapeutic targets for BC are of great significance. In our previous study, we found that prenylated rab acceptor 1 domain family member 2 (PRAF2) is an oncogene in BC. However, the exact mechanism of PRAF2 in BC cancer promotion is still not fully understood. Methods Pan-cancer analysis of PRAF2 was performed in the TIMER, Kaplan‒Meier, UALCAN and GEPIA databases. The prognostic value of PRAF2 in BC was investigated in the GEPIA database. The influence of PRAF2 on immune infiltration in BC was analyzed in theTISIDE and TIMER databases. Finally, we validated the expression of PRAF2 in our institutional samples. After downregulating PRAF2 in two BC cell lines, we tested cell proliferation by CCK-8 and Wound healing assays.  \nResults PRAF2 was highly expressed in various cancers, including BC, and in most BC cell lines. Higher expres  \nsion of PRAF2 indicated poorer overall survival (OS) but not disease-free survival (DFS) . Higher expression of PRAF2 is an independent prognostic factor in BC. PRAF2 is more highly expressed in BC than in the corresponding normal tissues. Downregulation of PRAF2 in BC can significantly inhibit viability and migration.  \nConclusions PRAF2 is highly expressed in various cancers, including BC. The expression of PRAF2 is related to Liquid– Liquid Phase Separation in BC. Finally, PRAF2 is upregulated in BC based on our institutional data. Downregulation of PRAF2 significantly inhibits cellular viability、 migration in BC. PRAF2 may be a potential biomarker and therapeutic target for BC.  \nKeywords PRAF2, Breast cancer, Molecular target, Immune infiltration, Novel biomarker  \n†Zheng Wang, Zilin Bi, Hongguang Bo and Junyi Xu contributed equally to this work.  \n*Correspondence:  \nYabing Wang [wangeb3@wnmc.edu.cn](wangeb3@wnmc.edu.cn)[ ](wangeb3@wnmc.edu.cn)Qian Zhang [qianzhang90@163.com](qianzhang90@163.com)[ ](qianzhang90@163.com)Jianping Chen[chenjianping2023@126.com](chenjianping2023@126.com)  \n1 Department of Thyroid and Breast Surgery, Yijishan Hospital, First Affiliated Hospital ofWannan Medical College, Zheshan West Rd No. 2, Wuhu, Anhui Province 241001, China  \n2 School of Basic Medical Science, Capital Medical University, No. 10 Right Outside the Western Headlines, Beijing 100069, China  \n3 Department of Oncology, Jiangdu People’s Hospital Affiliated to Medical College of Yangzhou University, 9 Dongfanghong Road, Jiangdu District, Jiangsu Province, Yangzhou 225299, China  \n4 Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, University Town, Xue Yuan Road 1, Fujian Province, Fuzhou 350122, China  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not p","cbCairVPbY4h8Mid","https://ap.wps.com/l/cbCairVPbY4h8Mid","pdf",3714055,21,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Breast cancer overview and need for targets\n## Rationale for PRAF2 and study aims\n# Methods and materials\n## Gene expression analysis","[{\"question\":\"What problem does the study address in breast cancer research?\",\"answer\":\"The study targets the need for novel therapeutic biomarkers, focusing on PRAF2 whose mechanism in breast cancer promotion is not fully understood.\"},{\"question\":\"How was the prognostic value of PRAF2 evaluated?\",\"answer\":\"Prognostic associations were analyzed using multiple databases, with specific investigation of prognostic value in GEPIA.\"},{\"question\":\"What experimental validation was performed after bioinformatics analysis?\",\"answer\":\"PRAF2 expression was validated in institutional breast cancer samples, and PRAF2 was downregulated in two breast cancer cell lines to test effects on viability, proliferation, and migration using assays such as CCK-8 and wound healing.\"}]","PRAF2 as a novel biomarker for breast cancer with machine learning and experimentation validation | PDF",1790175127,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14854eee8f7a39dd64681888f7415eda.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8dc1037ab5ba330933ed0cb764d80ea.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0cdd417ac70e56f0435404d221ccae00.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6f22e6708fb6effd1c3e1d74a246a45.webp",980,1301]